Novavax Inc. $NVAX shares experienced a sharp rise following the announcement that the US Food and Drug Administration (FDA) granted full approval for its Covid-19 vaccine. This development alleviated investor concerns after previous delays in authorization and public doubts voiced by US Secretary of Health and Human Services, Robert F. Kennedy Jr., regarding the product's effectiveness.

In recent days, shares of vaccine producer Novavax have experienced a steep decline of nearly 20% by market close. This drop came on the heels of remarks made by the U.S. Health and Human Services spokesperson Robert F. Kennedy Jr. during an interview with CBS News, where he raised concerns about the company’s COVID-19 vaccine. The news has stirred the financial markets, highlighting the critical balance between innovative breakthroughs and rigorous regulatory standards in the biotech industry.